106100-65-6 Usage
General Description
Fasiplon is a chemical compound that belongs to the class of non-benzodiazepine hypnotic agents, which are used for the treatment of insomnia. It acts as a selective agonist at the benzodiazepine site of the GABAA receptor, leading to its sedative and sleep-inducing effects. Fasiplon has been shown to improve various aspects of sleep, including reducing the time to fall asleep and increasing the duration of sleep. It has also demonstrated a favorable safety profile with minimal adverse effects, making it a potential option for the management of insomnia. However, further research is needed to fully understand its long-term efficacy and safety.
Check Digit Verification of cas no
The CAS Registry Mumber 106100-65-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,6,1,0 and 0 respectively; the second part has 2 digits, 6 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 106100-65:
(8*1)+(7*0)+(6*6)+(5*1)+(4*0)+(3*0)+(2*6)+(1*5)=66
66 % 10 = 6
So 106100-65-6 is a valid CAS Registry Number.
InChI:InChI=1/C13H15N5O2/c1-5-9-7(2)18-6-10(11-14-8(3)20-17-11)15-13(18)16-12(9)19-4/h6H,5H2,1-4H3
106100-65-6Relevant articles and documents
2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors
Tully,Gardner,Gillespie,Westwood
, p. 2060 - 2067 (2007/10/02)
Oxadiazoles, like the benzoyl group in a series of imidazo[1,2-a]pyrimidines, have been found to be metabolically stable alternatives to ester groups in benzodiazepine-receptor ligands. This change has lead to a number of compounds which bind to the receptors and which exhibit potent agonist activity in a food-motivated conflict test thought to predict anxiolytic properties. Compounds 4, 5, and 13 were equipotent with chlordiazepoxide but showed little or no myorelaxant effects. Replacing the oxadiazole group by thiazole gave compounds such as 23 which binds to the benzodiazepine receptor but exhibits the intrinsic activity of a partial inverse agonist in vivo.
